Summary
The AI claims largely reference Lipitor (atorvastatin) and multiple ibuprofen–Lipitor interactions/risk statements, but the supplied FDA label excerpts are only for CALDOLOR (ibuprofen injection). As a result, many claims are unsupported or not label-mappable. A few general NSAID bleeding-risk statements are directionally consistent with the CALDOLOR label, but the majority cannot be verified against the provided ibuprofen-only label text.
Category Scores
Accurate Statements
Ibuprofen can increase the risk of bleeding by making blood more prone to bleeding.
Supported only in part by CALDOLOR labeling describing serious GI bleeding risk with NSAIDs (e.g., 5.2 GI bleeding/ulceration/perforation). The AI phrasing is broader than what is explicitly stated ("blood more prone to bleeding").
The combination of atorvastatin (Lipitor) and ibuprofen may increase the risk of bleeding, kidney damage, and liver damage.
Bleeding portion is directionally consistent with NSAID GI bleeding risk (5.2). The additional kidney/liver risk and the specific atorvastatin–ibuprofen combination are not supported by the provided CALDOLOR (ibuprofen) label excerpts.
Unsupported Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels and prevent cardiovascular disease.
No Lipitor (atorvastatin) label excerpts were provided; evaluation cannot be mapped to the supplied prescribing information.
Lipitor (atorvastatin) works by inhibiting the production of cholesterol in the liver, thereby reducing low-density lipoprotein (LDL) cholesterol in the blood.
No Lipitor prescribing information provided in the prompt.
Taking ibuprofen with Lipitor may increase the risk of bleeding.
The provided label excerpts are for CALDOLOR (ibuprofen) only and do not describe atorvastatin–ibuprofen interactions.
The increased bleeding risk with ibuprofen and Lipitor may be particularly relevant for individuals with a history of bleeding disorders.
The provided CALDOLOR label excerpt lists risk factors for GI bleeding (e.g., prior peptic ulcer disease and/or GI bleeding, anticoagulant use, age), but does not mention "bleeding disorders" or connect that phrasing to ibuprofen+Lipitor.
The increased bleeding risk with ibuprofen and Lipitor may be particularly relevant for individuals taking anticoagulant medications.
CALDOLOR label excerpt supports increased GI bleeding risk with concomitant use of anticoagulants (5.2). However, the statement is framed specifically as ibuprofen + Lipitor, and Lipitor-related context is not supported by provided excerpts.
Both ibuprofen and Lipitor can affect kidney function.
CALDOLOR excerpts provided do not include kidney-function statements; also Lipitor information is not provided.
Taking ibuprofen with Lipitor may increase the risk of kidney damage or failure.
No kidney-damage/failure statements or ibuprofen+Lipitor interaction details are present in the supplied CALDOLOR excerpts.
Lipitor can cause liver damage in some individuals.
No Lipitor label excerpts provided.
Taking ibuprofen with Lipitor may increase the risk of liver damage.
The provided CALDOLOR excerpts do not address liver damage risk or ibuprofen+Lipitor combination effects.
Atorvastatin (Lipitor) should not be taken with NSAIDs, including ibuprofen, unless medically necessary and under close medical supervision.
No Lipitor label contraindication/interactions provided; also not supported by supplied CALDOLOR excerpts.
The FDA warns that combining statins (including Lipitor) with NSAIDs (including ibuprofen) may increase the risk of bleeding.
No statin (Lipitor) warnings are present in the supplied CALDOLOR label excerpts; the specific statin+NSAID combination warning is unsupported.
The FDA warns that combining statins (including Lipitor) with NSAIDs (including ibuprofen) may increase the risk of kidney damage.
No such statin+NSAID warning is included in the provided ibuprofen-only excerpts, and kidney damage language is not present.
The FDA warns that combining statins (including Lipitor) with NSAIDs (including ibuprofen) may increase the risk of liver damage.
No such statin+NSAID warning is included in the provided ibuprofen-only excerpts; liver damage language is not present.
Ibuprofen and Lipitor can interact with other medications.
No combined interaction data between ibuprofen and Lipitor is provided in the supplied excerpts.
Ibuprofen and Lipitor can interact with blood thinners.
While CALDOLOR 5.2 mentions anticoagulants as a GI bleed risk factor, the statement is framed as an interaction between ibuprofen and Lipitor (atorvastatin), not supported by provided excerpts.
Ibuprofen and Lipitor can interact with diabetes medications.
No diabetes-medication interaction information provided in the supplied CALDOLOR excerpts.
Ibuprofen and Lipitor can interact with certain antibiotics.
No antibiotic interaction information provided in the supplied CALDOLOR excerpts.
The combination of atorvastatin (Lipitor) and ibuprofen has been the subject of several patent applications.
Not supported by the supplied prescribing information excerpts.
Taking ibuprofen with Lipitor may increase the risk of kidney damage or failure.
Not supported by the provided CALDOLOR excerpts.
Taking ibuprofen with Lipitor may increase the risk of liver damage.
Not supported by the provided CALDOLOR excerpts.
Contradictions
Low
AI Statement
The FDA warns that combining statins (including Lipitor) with NSAIDs (including ibuprofen) may increase the risk of bleeding.
Label Reference
Not contradicted, but unsupported due to missing statin label content. Categorized as contradiction only if direct conflict exists, which cannot be confirmed from provided excerpts.
Important Omissions
CALDOLOR-specific dosage and administration instructions (lowest effective dose/shortest duration; max daily dose; dilution and infusion time) are not addressed in the AI claims.
Importance:
Moderate
CALDOLOR contraindications (e.g., hypersensitivity to ibuprofen/NSAIDs, post-CABG surgery) are not discussed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Most high-specificity claims about ibuprofen+Lipitor risks (kidney/liver, statin+NSAID warnings, medication-to-medication interactions) are unsupported by the provided ibuprofen (CALDOLOR) label excerpts. Claims that ibuprofen increases bleeding risk are directionally consistent with NSAID GI bleeding risk in the CALDOLOR label, but the AI extends beyond label-supported scope.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The AI response relies on Lipitor/statin interaction and risk statements that cannot be verified against the provided CALDOLOR (ibuprofen injection) label excerpts.
Suggested Improvement
Restrict claims to CALDOLOR (ibuprofen) label content provided (e.g., GI bleeding risk and known GI risk factors; avoid atorvastatin/statin combination-specific warnings unless the Lipitor label is supplied). Include only label-supported interaction information (e.g., aspirin interaction details from Table 3) and omit unlabelled kidney/liver damage and statin+NSAID warnings.